Expression of HMGB2 in peripheral blood T cells of ESCC patients and its relation-ship with clinicopathological parameters
Objective To study the expression level and clinical significance of high mobility group protein B2(HMGB2)in peripheral blood T lymphocytes of patients with esophageal squamous cell carcinoma(ESCC).Methods The expression of HMGB2 in peripheral blood T lymphocytes was detected by flow cytometry,RT-qPCR and Western blotting in 31 ESCC patients and 13 healthy subjects.The relationship between HMGB2 and pathological indexes was evaluated according to tumor stage and tissue differentiation.Results Compared with healthy controls,HMGB2 was highly expressed in CD4+ and CD8+ T cells in ESCC patients.The expression rate of HMGB2 in tumor stage Ⅰ-Ⅱ and Ⅲ-Ⅳ groups,as well as high,middle differentiation and low differentiation groups were significantly higher than those in healthy control group.The clinicopathological analysis showed that the expression rate of HMGB2 was higher in the low differentiation group than that in the high,middle differentiation group;the group with tumor tissue>5 cm was high-er than that with tumor tissue≤5 cm;the infiltration depth of T3-T4 group was higher than that of T1-T2 group;the clinical TNM stage Ⅲ-Ⅳ group was higher than the stage Ⅰ-Ⅱ group.Conclusion HMGB2 is highly expressed in T lymphocyte subsets of ESCC patients,and its expression is positively correlated with clinical TNM stage,histological differentiation degree,tumor size and invasion depth of ESCC patients.HMGB2 can be used as a potential biomarker and therapeutic target to evaluate the prognosis of ESCC patients.
Esophageal squamous cell carcinomaHigh mobility group protein 2T lymphocyte subsetsClinico-pathological parameter
NETL
NSTL
万方数据
维普
